Trial Profile
A Phase 3, Randomized, Double-blind, Multicenter, Placebo Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Inebilizumab (Primary)
- Indications Autoimmune disorders
- Focus Registrational; Therapeutic Use
- Acronyms MITIGATE
- Sponsors Amgen; Horizon Pharma USA; Viela Bio
- 06 Feb 2024 According to Amgen media release, Data readout is anticipated in H2 2024.
- 19 Jun 2023 This trial has been completed in Sweden, according to European Clinical Trials Database record.
- 23 May 2023 Status changed from recruiting to active, no longer recruiting.